Shilpa Pharma Lifesciences Limited, a 100% subsidiary of Shilpa Medicare Limited, has recently received the prestigious Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its API, Nifedipine.
Nifedipine, a calcium-channel blocker in the dihydropyridine subclass, is widely used for treating high blood pressure (hypertension) and chest pain (angina). By relaxing the blood vessels, it lowers blood pressure and eases the heart’s workload. Additionally, it helps increase blood and oxygen flow to the heart, alleviating angina symptoms.
The granting of CEP by EDQM highlights Shilpa Pharma Lifesciences’ commitment to producing high-quality APIs that meet global standards. This milestone reflects the company’s expertise in quality-driven pharmaceutical development and commercial production, reinforcing its position in the global market.
